全文获取类型
收费全文 | 777236篇 |
免费 | 48960篇 |
国内免费 | 1009篇 |
专业分类
耳鼻咽喉 | 10754篇 |
儿科学 | 26134篇 |
妇产科学 | 22904篇 |
基础医学 | 123288篇 |
口腔科学 | 21350篇 |
临床医学 | 65411篇 |
内科学 | 143935篇 |
皮肤病学 | 17910篇 |
神经病学 | 55273篇 |
特种医学 | 28987篇 |
外国民族医学 | 105篇 |
外科学 | 118814篇 |
综合类 | 15652篇 |
现状与发展 | 1篇 |
一般理论 | 261篇 |
预防医学 | 56874篇 |
眼科学 | 18411篇 |
药学 | 58645篇 |
中国医学 | 1691篇 |
肿瘤学 | 40805篇 |
出版年
2018年 | 8134篇 |
2016年 | 6754篇 |
2015年 | 7618篇 |
2014年 | 10174篇 |
2013年 | 15994篇 |
2012年 | 20837篇 |
2011年 | 22432篇 |
2010年 | 13731篇 |
2009年 | 12727篇 |
2008年 | 21332篇 |
2007年 | 23059篇 |
2006年 | 23156篇 |
2005年 | 22194篇 |
2004年 | 21665篇 |
2003年 | 20543篇 |
2002年 | 20048篇 |
2001年 | 35628篇 |
2000年 | 36989篇 |
1999年 | 30589篇 |
1998年 | 8099篇 |
1997年 | 7209篇 |
1996年 | 7364篇 |
1995年 | 6873篇 |
1994年 | 6432篇 |
1993年 | 6151篇 |
1992年 | 23101篇 |
1991年 | 23693篇 |
1990年 | 23673篇 |
1989年 | 22878篇 |
1988年 | 21045篇 |
1987年 | 20645篇 |
1986年 | 19544篇 |
1985年 | 18745篇 |
1984年 | 13863篇 |
1983年 | 11891篇 |
1982年 | 6792篇 |
1979年 | 13437篇 |
1978年 | 9771篇 |
1977年 | 8259篇 |
1976年 | 7862篇 |
1975年 | 8945篇 |
1974年 | 10683篇 |
1973年 | 10193篇 |
1972年 | 9782篇 |
1971年 | 9375篇 |
1970年 | 8770篇 |
1969年 | 8280篇 |
1968年 | 7878篇 |
1967年 | 7195篇 |
1966年 | 6531篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
O Schouten J H H van Laanen E Boersma R Vidakovic H H H Feringa M Dunkelgrün J J Bax J Koning H van Urk D Poldermans 《European journal of vascular and endovascular surgery》2006,32(1):21-26
OBJECTIVE: To evaluate the effect of statins on aneurysm growth in a group of consecutive patients under surveillance for infrarenal aortic aneurysms (AAA). MATERIALS AND METHODS: All patients (59 statin users, 91 non-users) under surveillance between January 2002 and August 2005 with a follow-up for aneurysm growth of at least 12 months and a minimum of three diameter evaluations were retrospectively included in the analysis. Multiple regression analysis, weighted with the number of observations, was performed to test the influence of statins on AAA growth rate. RESULTS: During a median period of 3.1 (1.1-13.1) years the overall mean aneurysm growth rate was 2.95+/-2.8 mm/year. Statin users had a 1.16 mm/year lower AAA growth rate compared to non-users (95% CI 0.33-1.99 mm/year). Increased age was associated with a slower growth (-0.09 mm/year per year, p = 0.003). Female gender (+1.82 mm/year, p = 0.008) and aneurysm diameter (+0.06 mm/year per mm, p = 0.049) were associated with increased AAA growth. The use of non-steroidal anti-inflammatory drugs, chronic lung disease, or other cardiovascular risk factors were not independently associated with AAA growth. CONCLUSIONS: Statins appear to be associated with attenuation of AAA growth, irrespective of other known factors influencing aneurysm growth. 相似文献
82.
83.
Published data devoted to making and characterization of the properties of polymeric wound dressings with proteolytic action
are reviewed. These data are indicative of individual dependence of the physicochemical properties, activity, and stability
of each particular enzyme on the type of polymer matrix and the method of immobilization. In order to obtain wound dressings,
which are active in physiological medium and retain their activity upon sterilization, it is necessary to optimize the composition
and characteristics of a polymer matrix and the enzyme included into its structure.
__________
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 40, No. 8, pp. 24–28, August, 2006. 相似文献
84.
D Yinon L Lowenstein S Suraya R Beloosesky O Zmora A Malhotra G Pillar 《The European respiratory journal》2006,27(2):328-333
Pre-eclamptic toxaemia (PET) may be associated with both endothelial dysfunction (ED) and sleep-disordered breathing (SDB). It was hypothesised that females with PET would demonstrate both SDB and ED, and that a correlation between these two would suggest a potential causative association. A total of 17 females with PET and 25 matched females with uncomplicated pregnancy were studied. They underwent a nocturnal ambulatory sleep study (using Watch_PAT100) and noninvasive evaluation of endothelial function utilising the reactive hyperaemia test (using Endo_PAT 2000). A higher ratio of post- to pre-occlusion pulse-wave amplitude (endothelial function index (EFI)) indicated better endothelial function. Females with PET had a significantly higher respiratory disturbance index (RDI) and lower EFI than controls (18.4+/-8.4 versus 8.3+/-1.3.h(-1), and 1.5+/-0.1 versus 1.8+/-0.1, respectively). Blood pressure significantly correlated with RDI and with EFI. EFI tended to correlate with RDI. In conclusion, these results suggest that both sleep-disordered breathing and endothelial dysfunction are more likely to occur in females with pre-eclamptic toxaemia than in females with uncomplicated pregnancies. The current authors speculate that respiratory disturbances contribute to the functional abnormality of the blood vessels seen in females with pre-eclamptic toxaemia, although causality cannot be determined based on this study. 相似文献
85.
R H Green C E Brightling S McKenna B Hargadon N Neale D Parker C Ruse I P Hall I D Pavord 《The European respiratory journal》2006,27(6):1144-1151
There is increasing evidence that the assessment of eosinophilic airway inflammation using induced sputum and measurement of airway hyperresponsiveness provides additional, clinically important information concerning asthma control. The aim of this study was to directly compare the effects of different treatments on these markers in patients with asthma and persistent symptoms, despite the use of low-dose inhaled corticosteroids. A double-blind four-way crossover study was performed, which compared a 1-month treatment with budesonide 400 mug b.i.d., additional formoterol, additional montelukast and placebo in 49 patients with uncontrolled asthma despite budesonide 100 mug b.i.d., with each treatment separated by a 4-week washout period. The change in sputum eosinophil count with formoterol (2.4 to 3.8% change, 0.6-fold reduction, 95% confidence interval (CI) 0.5-0.9) differed significantly from placebo (2.8 to 2.5% change, 1.1-fold reduction, 95% CI 0.7-1.6) and high-dose budesonide (2.7 to 1.6% change, 1.6-fold reduction, 95% CI 1.2-2.2). The effects of montelukast did not differ from placebo. The changes in methacholine airway responsiveness were small and did not differ between treatments. High-dose budesonide had the broadest range of beneficial effects on other outcomes, including symptom scores, morning peak expiratory flow and forced expiratory volume in one second. In conclusion, treatment given in addition to low-dose inhaled corticosteroids results in modest benefits. Formoterol and high-dose budesonide have contrasting effects on eosinophilic airway inflammation. 相似文献
86.
J Müller-Quernheim K I Gaede E Fireman G Zissel 《The European respiratory journal》2006,27(6):1190-1195
An increase in chronic beryllium disease (CBD) has been suggested due to higher industrial use of beryllium alloys. Since occupational CBD is a perfect phenocopy of sarcoidosis, it might be misdiagnosed as sarcoidosis. In the current it was hypothesised that CBD exists in cohorts of sarcoidosis patients. In a prospective case study, sarcoidosis patients were evaluated for potential beryllium exposure. In those patients in whom beryllium exposure was confirmed and beryllium hypersensitivity demonstrated, the diagnosis of sarcoidosis was rejected and corrected to CBD. In 84 patients seen for re-evaluation or making a diagnosis of sarcoidosis, beryllium exposure was recognised and a diagnosis of CBD was made in 34 out of 84 patients. The time lag between clinical diagnosis of sarcoidosis and the final diagnosis of CBD ranged 0-18 yrs (median 3 yrs) and the mean (range) age at time of diagnosis of CBD was 43.9(25-80) yrs. Beryllium-contaminated workplaces causing disease encompassed a wide spectrum of industries and technical trades in which beryllium-exposure is generally not perceived as a health hazard. In conclusion, chronic beryllium disease still belongs to the spectrum of differential diagnoses of granulomatous disorders. 相似文献
87.
88.
89.
Severe adverse effects during the use of ovulation inhibitors occur mostly in women who have an elevated risk for the development of certain diseases owing to hereditary or acquired factors. By means of a careful personal or family history analysis as well as specific laboratory examinations, an existing predisposition may frequently be diagnosed and the individual risk associated with the use of oral contraceptive inhibitors may be estimated. The present contribution describes the potential effects of treatment with ovulation inhibitors on women with thrombophilia, cardiovascular disease, diabetes mellitus, dyslipidemia, overweight or underweight, tumors, psychiatric and neurological diseases and autoimmune disease. The hormonal methods and non-hormonal alternatives available for contraception are elucidated according to existing lesions and risk factors and the advantages and disadvantages are discussed. 相似文献
90.
J.L. Bernat A.M. D'Alessandro F.K. Port T.P. Bleck S.O. Heard J. Medina S.H. Rosenbaum M.A. DeVita R.S. Gaston R.M. Merion M.L. Barr W.H. Marks H. Nathan K. O'Connor D.L. Rudow A.B. Leichtman P. Schwab N.L. Ascher R.A. Metzger V. Mc Bride W. Graham D. Wagner J. Warren F.L. Delmonico 《American journal of transplantation》2006,6(2):281-291
A national conference on organ donation after cardiac death (DCD) was convened to expand the practice of DCD in the continuum of quality end-of-life care. This national conference affirmed the ethical propriety of DCD as not violating the dead donor rule. Further, by new developments not previously reported, the conference resolved controversy regarding the period of circulatory cessation that determines death and allows administration of pre-recovery pharmacologic agents, it established conditions of DCD eligibility, it presented current data regarding the successful transplantation of organs from DCD, it proposed a new framework of data reporting regarding ischemic events, it made specific recommendations to agencies and organizations to remove barriers to DCD, it brought guidance regarding organ allocation and the process of informed consent and it set an action plan to address media issues. When a consensual decision is made to withdraw life support by the attending physician and patient or by the attending physician and a family member or surrogate (particularly in an intensive care unit), a routine opportunity for DCD should be available to honor the deceased donor's wishes in every donor service area (DSA) of the United States. 相似文献